Shares of Bio-Reference Laboratories (BRLI -9.5%) get hammered, despite its FQ3 beating on its bottom line earlier today. Net earnings rose 25% Y/Y, as the clinical-testing company's streak of double-digit revenue growth continued, but investors appear to be taking advantage of near 52-week highs to lock in profits as sales growth shows signs of stagnating.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs